| 2024/09/03 | Revolutionary Treatment for Dry Eye: AG-80308 by 新源生技 Allgenesis |
| 2024/08/11 | How 新源生技 Allgenesis Evaluated Unique Endpoints to Advance its Phase 2 DME Study (Lexitas) |
| 2024/08/11 | How 新源生技 Allgenesis Evaluated Unique Endpoints to Advance its Phase 2 DME Study (Voxeleron) |
| 2024/02/15 | OIS: Ophthalmology Innovation Source: 新源生技 Allgenesis Biotherapeutics | Sunil Patel, MD, PhD, Chief Medical Officer |
| 2023/11/17 | 新源生技 Allgenesis announces positive early results for its AG-73305 phase 2a Diabetic Macular Edema study at the American Academy of Ophthalmology |
| 2023/11/13 | 新源生技 Allgenesis：鼓舞人心的AG-73305臨床 2a試驗數據顯示了初步安全性和有效性 |
| 2023/11/13 | 新源生技 Allgenesis Announces Encouraging Preliminary Safety and Efficacy Data from the AG-73305 Phase 2a Trial for the Treatment of Diabetic Macular Edema at American Academy of Ophthalmology |
| 2023/11/08 | 新源生技 Allgenesis Announces Encouraging Preliminary Safety and Efficacy Data from the AG-73305 Phase 2a Trial for the Treatment of Diabetic Macular Edema at American Academy of Ophthalmology |
| 2023/11/07 | AAO 2023: 新源生技 Allgenesis Biotherapeutics presents Phase IIa data of AG-73305 for DME |
| 2023/06/19 | 新源生技 Allgenesis announces Phase 1b data showing AG-80308 providing improvements in dry eye patients |
